Looking toward 2034, the Tumor Marker Testing Market is poised for sustained, long-term growth. The combination of an aging global demographic and the continuous rollout of innovative therapies ensures a consistent demand for diagnostics. As new classes of cancer therapies enter the market, they will each require their own corresponding diagnostic companion tests, further fueling the market...